183 related articles for article (PubMed ID: 21854558)
1. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma.
Lieber J; Eicher C; Wenz J; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
BMC Cancer; 2011 Aug; 11():362. PubMed ID: 21854558
[TBL] [Abstract][Full Text] [Related]
2. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
[TBL] [Abstract][Full Text] [Related]
3. BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma.
Lieber J; Ellerkamp V; Vogt F; Wenz J; Warmann SW; Fuchs J; Armeanu-Ebinger S
Exp Cell Res; 2014 Mar; 322(1):217-25. PubMed ID: 24355809
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells.
Lieber J; Ellerkamp V; Wenz J; Kirchner B; Warmann SW; Fuchs J; Armeanu-Ebinger S
Pediatr Surg Int; 2012 Feb; 28(2):149-59. PubMed ID: 21971946
[TBL] [Abstract][Full Text] [Related]
6. The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma.
Lieber J; Armeanu-Ebinger S; Fuchs J
Int J Mol Sci; 2015 Feb; 16(2):4190-208. PubMed ID: 25690034
[TBL] [Abstract][Full Text] [Related]
7. The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic.
Bieghs L; Lub S; Fostier K; Maes K; Van Valckenborgh E; Menu E; Johnsen HE; Overgaard MT; Larsson O; Axelson M; Nyegaard M; Schots R; Jernberg-Wiklund H; Vanderkerken K; De Bruyne E
Oncotarget; 2014 Nov; 5(22):11193-208. PubMed ID: 25008202
[TBL] [Abstract][Full Text] [Related]
8. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin rescues ABT-737 efficacy in small cell lung cancer.
Gardner EE; Connis N; Poirier JT; Cope L; Dobromilskaya I; Gallia GL; Rudin CM; Hann CL
Cancer Res; 2014 May; 74(10):2846-56. PubMed ID: 24614082
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC.
Potter DS; Galvin M; Brown S; Lallo A; Hodgkinson CL; Blackhall F; Morrow CJ; Dive C
Mol Cancer Ther; 2016 Jun; 15(6):1248-60. PubMed ID: 27197306
[TBL] [Abstract][Full Text] [Related]
11. Glycycoumarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis.
Zhang E; Yin S; Lu X; Ye L; Fan L; Hu H
Nutrients; 2018 Mar; 10(3):. PubMed ID: 29543705
[TBL] [Abstract][Full Text] [Related]
12. BH3 mimetics reduce adhesion and migration of hepatoblastoma and hepatocellular carcinoma cells.
Vogt F; Lieber J; Dewerth A; Hoh A; Fuchs J; Armeanu-Ebinger S
Exp Cell Res; 2013 Jun; 319(10):1443-50. PubMed ID: 23416067
[TBL] [Abstract][Full Text] [Related]
13. The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
Reuland SN; Goldstein NB; Partyka KA; Cooper DA; Fujita M; Norris DA; Shellman YG
PLoS One; 2011; 6(8):e24294. PubMed ID: 21897876
[TBL] [Abstract][Full Text] [Related]
14. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
[TBL] [Abstract][Full Text] [Related]
15. Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts.
Eicher C; Dewerth A; Thomale J; Ellerkamp V; Hildenbrand S; Warmann SW; Fuchs J; Armeanu-Ebinger S
Br J Cancer; 2013 Feb; 108(2):334-41. PubMed ID: 23257893
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 modulation to activate apoptosis in prostate cancer.
Bray K; Chen HY; Karp CM; May M; Ganesan S; Karantza-Wadsworth V; DiPaola RS; White E
Mol Cancer Res; 2009 Sep; 7(9):1487-96. PubMed ID: 19737977
[TBL] [Abstract][Full Text] [Related]
17. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells.
Ruvolo PP; Ruvolo VR; Benton CB; AlRawi A; Burks JK; Schober W; Rolke J; Tidmarsh G; Hail N; Davis RE; Andreeff M
Biochim Biophys Acta; 2016 Apr; 1863(4):562-71. PubMed ID: 26704388
[TBL] [Abstract][Full Text] [Related]
18. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
Hann CL; Daniel VC; Sugar EA; Dobromilskaya I; Murphy SC; Cope L; Lin X; Hierman JS; Wilburn DL; Watkins DN; Rudin CM
Cancer Res; 2008 Apr; 68(7):2321-8. PubMed ID: 18381439
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics.
Mattoo AR; Zhang J; Espinoza LA; Jessup JM
Clin Cancer Res; 2014 Nov; 20(21):5446-55. PubMed ID: 25208882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
